Deucrictibant

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Strong financial position with cash and cash equivalents of €318 million as of June 30, 2026 ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update. “Pharvaris continues to make strong progress advancing deucrictibant IR toward potential regulatory approval, moving closer to our goal of helping address unmet needs of people living with HAE by providing a therapy that can offer rapid and sustained attack relief and resolution with a single oral capsule. In parallel to our recent regulatory successes, our ongoing pre-commercial activities are designed to support a timely, successful U.S. launch,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Announcing pivotal data from CHAPTER-3, expected this quarter, will mark another key milestone for Pharvaris as we develop deucrictibant for both the prevention and on-demand treatment of bradykinin-mediated angioedema attacks. The financing we completed in May extends our cash runway into 2028, enabling us to properly prepare for deucrictibant’s launch and consider lifecycle management opportunities while maintaining capital discipline.” Recent Business Updates Development Pipeline Topline data from CHAPTER-3 ( NCT06669754 ) expected in 3Q2026. CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release (XR) tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE. Eighty-five participants were enrolled and randomized in a 2:1 ratio to receive deucrictibant XR (40 mg/day), the intended commercial formulation, or placebo, once daily for 24 weeks. Pharvaris expects to announce topline data from CHAPTER-3 in the third quarter of 2026. Enrollment in CHAPTER-4 ( NCT06679881 ) progressing as planned. CHAPTER-4 is a long-term, open-label extension study of orally administered deucrictibant XR (40 mg/day) for the prophylactic treatment of HAE attacks. The goal of the study is to evaluate the long-term safety and effectiveness of deucrictibant XR in the prophylactic treatment of HAE attacks. Review of marketing authorization applications of deucrictibant immediate-release (IR) capsule as a potential on-demand treatment of HAE attacks underway by regulatory authorities. In July 2026, the U.S. Food and Drug Administration (FDA) accepted to review the Company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks, with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027. In July 2026, the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for deucrictibant IR and began its formal review of the MAA under the centralized procedure. Expanded Access Program (EAP) for deucrictibant IR for the on-demand treatment of HAE attacks opened in the U.S. EAPs are a potential pathway for people with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. The U.S. EAP for deucrictibant IR is available to people in U.S. living with HAE meeting eligibility requirements. Healthcare professionals interested in making requests for access to deucrictibant IR through the EAP can refer to and/or email Pharvaris’ Medical Affairs at expandedaccess@pharvaris.com . Enrollment in CREAATE ( NCT07266805 ) progressing as planned. CREAATE is a global, pivotal Phase 3 study evaluating orally administered deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. Assessment of AAE-C1INH disease burden and validation of clinical trial endpoints published in Frontiers in Immunology . Qualitative interviews provided evidence of the impact of AAE-C1INH on participants’ lives and overall well-being, and the study findings informed the clinical outcome assessment strategy for CREAATE, the first phase 3 clinical trial specifically studying AAE-C1INH. Evidence supporting bradykinin B2 receptor as a validated therapeutic target in bradykinin-mediated angioedema published in Clinical Reviews in Allergy & Immunology . This summary of the growing body of evidence explores the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema and supports bradykinin B2 receptor antagonism as a therapeutic strategy for bradykinin-mediated diseases, including HAE and AAE-C1INH, as well as, potentially, other allergic and immunological conditions. Corporate ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Peng Lu, M.D., Ph.D., promoted to newly created role of President. Leveraging the company’s scientific rigor and reflecting the depth of Dr. Lu’s contributions, Pharvaris has brought its research, development, and commercial functions under one leadership structure by promoting Dr. Lu to President, effective June 2026, strengthening Pharvaris’ ability to deliver on its strategic priorities. Closed $132 million underwritten offering. The proceeds from the offering of $132.3 million of shares extends cash runway into 2028. Upcoming Investor Events Wells Fargo 21st Annual Healthcare Conference. Boston, MA, Sept. 8-10, 2026. Format: Fireside Chat Date, time: Wednesday, Sept. 9, 4:30 p.m. EDT 2026 Cantor Global Healthcare Conference. New York, NY, Sept. 9-11, 2026. Format: Fireside Chat Date, time: Thursday, Sept. 10, 1:00 p.m. EDT Morgan Stanley 24th Annual Global Healthcare Conference. New York, NY, Sept. 14-16, 2026. Format: Fireside Chat Date, time: Tuesday, Sept. 15, 7:45 a.m. EDT H.C. Wainwright 28th Annual Global Investment Conference. New York, NY, Sept. 14-16, 2026. Format: Fireside Chat Date, time: Wednesday, Sept. 16, 8:00 a.m. EDT Live audio webcasts of the presentations will be available on the Investors section of the Pharvaris website at: . The audio replays will be available on Pharvaris’ website for 30 days following the presentation. Upcoming Medical Congress Presentations Bradykinin Symposium 2026. Berlin, September 3-4, 2026. Details for the accepted presentations at the 8 th Bradykinin Symposium are as follows: Title: Modelling human, rat, and humanized bradykinin B2 receptor-deucrictibant complexes in-silico Presenter: Niklas Piet Doering, Ph.D. Format: Oral Presentation Abstract ID: 158012 Date, time: Thursday, September 3, 14:55-15:05 CEST (8:55-9:05 a.m. EDT) Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial Presenter: Marc A. Riedl, M.D., M.S. Format: Oral Presentation Abstract ID: 158394 Date, time: Friday, September 4, 9:20-9:30 CEST (3:20-3:30 a.m. EDT) Title: Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant Presenter: Brigitte Loenders, Ph.D. Format: Poster Presentation Abstract ID: 157799 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: Evaluating Safety Margins of the Use of Deucrictibant Immediate-Release Capsule in Combination With Deucrictibant Extended-Release Tablet Presenter: Juan Bravo, Ph.D. Format: Poster Presentation Abstract ID: 157800 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema Presenter: Emel Aygören-Pürsün, M.D. Format: Poster Presentation Abstract ID: 157804 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema Presenter: Marcin Stobiecki, M.D., Ph.D. Format: Poster Presentation Abstract ID: 157807 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: End Of Progression of Attack Manifestations With Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks in the Phase 3 RAPIDe-3 Trial Presenter: Henriette Farkas, M.D., Ph.D., D.Sc. Format: Poster Presentation Abstract ID: 158385 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: End-of-Progression Using Patient Global Impression of Change Validation in RAPIDe-3 Presenter: Danny M. Cohn, M.D., Ph.D. Format: Poster Presentation Abstract ID: 158405 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: LC-MS particle-based plasma proteomics in bradykinin-mediated angioedema Presenter: Jonathan DeGeer, Ph.D. Format: Poster Presentation Abstract ID: 158979 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Title: The NHP Bradykinin Challenge Model Predicts Human Deucrictibant Efficacious Doses Presenter: Juan Bravo, Ph.D. Format: Poster Presentation Abstract ID: 159172 Date, time: Friday, September 4, 16:05-16:45 CEST (10:05-10:45 a.m. EDT) Financials Second Quarter 2026 Financial Results Liquidity Position. Cash and cash equivalents were €318 million as of June 30, 2026, compared to €292 million for December 31, 2025. Research and Development (R&D) Expenses. R&D expenses were €35.0 million for the quarter ended June 30, 2026, compared to €29.6 million for the quarter ended June 30, 2025. General and Administrative (G&A) Expenses. G&A expenses were €15.8 million for the quarter ended June 30, 2026, compared to €10.8 million for the quarter ended June 30, 2025. Loss for the quarter. Loss for the second quarter was €47.8 million, resulting in basic and diluted loss per share of €0.70 for the quarter ended June 30, 2026, compared to €45.5 million, or basic and diluted loss per share of €0.83, for the quarter ended June 30, 2025. Note on International Financial Reporting Standards (IFRS) Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency. About Deucrictibant Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic. About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit . Forward Looking Statements This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “hope,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CHAPTER-3, and CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release. Contact Maggie Beller Vice President, Head of Corporate and Investor Communications maggie.beller@pharvaris.com

Pharvaris（NASDAQ：PHVS）的核心资产deucrictibant是一款口服小分子缓激肽B2受体拮抗剂，正同时推进HAE按需治疗与预防适应症。2026年7月，FDA已受理其按需NDA，PDUFA日期为2027年4月23日；预防性Phase 3试验CHAPTER-3顶线数据预计于2026年第三季度读出。RAPIDe-3在按需治疗中显示症状缓解中位时间1.28小时（vs安慰剂>12小时），CHAPTER-1在预防治疗中降低84.5%月度发作率。但上述疗效在跨试验比较、监管审评以及长期安全性层面均存在尚未消弭的不确定性。以下从科学机制、按需疗效、预防价值、安全性、财务状况和竞争格局六个方面展开分析。 科学机制已由icatibant验证， 但口服形式需证明足够快的暴露 B2受体是HAE治疗中经过临床验证的靶点，其有效性由注射型B2R拮抗剂Firazyr（icatibant）在Phase 3试验FAST-3中证实：icatibant组症状缓解中位时间2.0小时vs安慰剂19.8小时（p<0.001）。 这一证据确认阻断B2R可终止HAE发作，因此Pharvaris无需承担靶点未经验证的风险。其核心科学问题转为：口服给药能否在发作早期达到足够快的暴露，以及小分子长期每日暴露是否安全。 Deucrictibant的体外效力约为icatibant的20–25倍（公司PK/PD模型数据），IR制剂在15–30分钟内达到模型预测的有效浓度EC85。 在RAPIDe-3中，攻击停止进展的中位时间为17.47分钟（vs安慰剂228.67分钟），与PK模型的早期暴露方向一致。然而，此类数据主要来自体外试验及公司内部模型，尚不能视为临床头对头优效证据。症状缓解的1.28小时在跨试验数字上优于Ekterly FDA标签中的2.0小时和icatibant的2.0小时，但两项试验的终点定义、安慰剂行为、统计截尾方式均不同，不能直接得出优效结论。 按需治疗疗效显著， 但首个口服按需药物已形成先发竞争 但IR的NDA仍处于FDA审评中，且首个口服按需药物Ekterly（sebetralstat）已于2025年7月3日获批，形成先发优势。 Ekterly在KONFIDENT试验中，600mg组症状开始缓解中位时间为1.79小时（vs安慰剂6.72小时），FDA标签中位数为2.0小时。Chiesi以约19亿美元收购KalVista，将推动Ekterly的商业化。2025年Ekterly全球净产品收入约4910万美元，2026年第一季度3930万美元，验证了口服按需市场的商业需求。deucrictibant若获批，需要在处方集中的定位、定价等方面与已建立医生习惯的Ekterly竞争。 -FDA对deucrictibant的PDUFA为2027年4月23日，标准审评周期（未获优先审评）。 -按需治疗中，deucrictibant在跨试验数字上表现出更快的症状缓解（1.28h vs 2.0h）和更低的救援药使用率（93.2%未使用救援药），但此类差异是否足以转化为处方偏好，取决于最终标签内容和真实世界数据。 -公司计划自建美国销售队伍，但商业化能力尚未经过验证。 预防价值取决于CHAPTER-3 能否复制Phase 2的结果 CHAPTER-1（Phase 2，N=34，12周）显示deucrictibant XR 40mg/日相对安慰剂降低84.5%月度发作率（p=0.0008），但样本量小、治疗期短，效果可能被高估。 该试验中，40mg组LS均值月度发作率为0.30，安慰剂组为1.93。CHAPTER-1开放标签扩展（OLE）随访超过1.5年，约80%患者实现≥90%的基线发作率降低，55.2%在分析期无发作，且公司称未发现新安全性信号。但OLE数据尚未经同行评议完整发表。 CHAPTER-3（Phase 3，N=81，2：1随机，24周）是近期最大的二元催化剂，预计2026年第三季度读出。 如果该试验复制84.5%的降低幅度，Pharvaris将形成“同一活性成分覆盖按需+预防”的产品组合，这是其与单一适应症竞争者相比的独特优势。若失败，预计将显著削弱公司估值中的预防市场部分，因为预防适应症的市场规模远大于按需（参见下文竞争格局）。 预防市场的现有竞争者已提供多种选择，如下表所示： Orladeyo是唯一已获批的口服预防药，但疗效数字远低于注射类产品，且存在胃肠道AE限制。 若deucrictibant XR能在更大样本中实现接近注射剂的疗效且耐受性良好，则有望从Orladeyo和注射产品中获取份额。但CHAPTER-3仅81人，属小型试验，少数高频发作患者可能对结果产生较大影响。 安全性历史临床暂停已解除， 但长期预防用药风险高于按需 Pharvaris在2022年因重复给药大鼠的非临床发现遭遇FDA临床暂停，按需IND于2023年6月解除，预防IND于2024年1月解除，但该事件表明监管机构对长期毒性持谨慎态度。 FDA认为该发现不太可能由B2R拮抗机制导致，但要求完成26周啮齿类毒理研究。目前临床未出现明确肝毒性、严重治疗相关不良事件或剂量限制性毒性。然而，已公开的安全性数据库规模有限： -RAPIDe-3中134人入组，113人至少一次给药，无治疗相关SAE或因TEAE停药，但具体常见AE（如头痛、胃肠道反应）发生率尚未完整公布。 -CHAPTER-1仅34人、12周，所有治疗相关TEAE均为轻度。 -XR的长期暴露（OLE >1.5年）虽未见新信号，但样本量小，且缺乏独立审评。 预防性用药需要每日给药，累积暴露远高于按需的偶发使用，安全性门槛更高。 KVD824（KalVista的口服预防小分子）曾因7/33人出现3–4级肝酶升高而终止试验，表明口服小分子预防药的肝毒性风险不可忽视。deucrictibant与KVD824作用机制（B2R拮抗 vs 激肽释放酶抑制）不同，但该失败案例提示市场：长期每日暴露的安全性验证需要更大的数据库和更长的随访。 现金跑道覆盖主要催化剂， 但无收入高烧钱仍为财务隐忧 截至2026年3月31日，Pharvaris持有现金€247.0百万；2026年5月融资净募资约$107.5百万，管理层预计跑道可延至2028年。 但公司自成立以来无产品收入，2024年净亏损€134.2百万，2025年€175.7百万，2026年第一季度经营现金流出€48.8百万。以年化经营现金流出约€195百万计算，融资后现金可覆盖CHAPTER-3读取、PDUFA及初步商业化准备，但若预防项目成功，全球申报、库存建设、销售基础设施等支出可能使公司仍需在2027–2028年再次融资。 研发支出结构显示按需项目的支出已随RAPIDe-3完成而下降（2026Q1 vs 2025Q1减少51%），预防XR和AAE-C1INH项目持续投入。 2026Q1总R&D支出€30.2百万，其中预防XR占€8.37百万，AAE-C1INH占€2.34百万（同比大幅增加）。公司尚无任何商业化合作伙伴公开披露，当前策略倾向于保留美国权益自营。 竞争格局完整对比： 按需市场与预防市场各有强敌 ### 按需治疗市场 Ekterly是最直接的竞争者，其先发优势及Chiesi的资金实力对Pharvaris构成显著挑战。 但deucrictibant在跨试验比较中显示出更快的症状缓解和更低的救援药需求，若最终标签允许无食物限制并覆盖HAE-nC1INH群体，仍可争取差异化。 ### 预防治疗市场 产品 机制与给药 关键Phase 3结果 每年费用（WAC估算） 获批时间 Orladeyo (berotralstat) 口服激肽释放酶抑制剂，QD 降低44.2% ~$632k 2020年 Takhzyro (lanadelumab) 皮下单抗，每2–4周 降低87% ~$500–600k 2018年 Haegarda (C1-INH SC) 皮下血浆C1-INH，每周2次 中位降低95.1% ~$500–700k 2017年 Deucrictibant XR 口服B2R拮抗剂，QD 降低84.5% (Phase 2) 待定 未获批 如果CHAPTER-3成功，deucrictibant XR将是同时具备口服便利性和高疗效数字的预防药（尚未被临床验证）。 但Orladeyo虽疗效较低，已建立处方基础；Takhzyro与Haegarda的注射负担在HAE患者中是否构成关键障碍，尚取决于个体选择。 关键风险与催化剂日历 ### 主要风险 ### 催化剂时间线 时间 事件 方向性2026年第三季度 CHAPTER-3 Phase 3顶线数据 最大近期二元事件 2026年下半年 RAPIDe-3完整同行评议、OLE长期安全数据 支持或削弱差异化 2026–2027年 全球MAA提交或受理 扩大商业机会2027年4月23日 IR美国PDUFA 按需产品批准决策 2027年 潜在美国商业上市 首次收入 Pharvaris当前状态为“按需适应症具备中高获批概率，预防适应症价值高但仍为二元结果，商业执行风险正在上升”的后期罕见病生物技术公司。其最吸引人的情景是CHAPTER-3复制Phase 2疗效、IR顺利获批，且两者形成组合价值；而最不利的情景则是预防失败或安全性问题，导致公司缩窄为仅有按需适应症的后进竞争者。投资者需评估自身对CHAPTER-3结果的不确定性容忍度，以及预防市场估值在投资论点中的权重。 以上是久谦的生物医药研究团队本次的主要内容。之后我们还会继续推出一系列海外生科公司前沿生物医药研究文章。获取更多深度解析，敬请关注我们的公众号。我们将为您带来更多独家的海外创新药数据解读、管线与机制拆解、真实世界研究与交易案例分析与前沿趋势研判，助您保持领先认知，掌握全球生物医药信息差。 我们自 2023 年起开始持续、系统性地追踪海外生物医药领域的创新药研发演进，重点覆盖创新药物作用机制（MOA）、平台型技术路径及其临床与商业化验证进展，涵盖上百家欧美及其他海外市场的主流 / 前沿生物科技公司。 我们已逐步构建起一套以机制可重复性与商业可扩展性为核心的研究分析框架，完善了针对不同技术平台、适应症与研发阶段的多维度评估指标，并基于大量横向机制对比与临床、BD 及商业化场景的交叉验证，沉淀出对技术成熟度、应用边界与长期价值创造潜力的专业洞见。 关于我们： 我们是久谦旗下的生物医药研究团队，专注于创新药研发、生命科学工具、医疗技术平台及生物医药产业链等领域的研究，提供包含但不限于商业尽职调查、管线与机制评估、竞争格局分析、行业与赛道研究等服务类型。我们致力于对早期技术路径与行业演进过程进行系统性研究与持续跟踪，助力投资人与企业在关键技术周期中形成认知优势与高质量决策支持。我们相信，唯有基于一线研究与数据与事实驱动的真实洞察，才能为客户提供真正可落地、可验证的研究结论。 若您有意向与我们进一步交流或合作，请扫描下方二维码联系我们： 您对这篇文章的信息和观点有何见解？欢迎在评论区与我们交流！